PSYDefiance Next Gen Altered Experience ETF
PSY Fund Description
PSY tracks a market-cap-weighted index of North American companies focused on psychedelics, medical cannabis, and ketamine for medicinal and health treatment purposes.
PSY Factset Analytics Insight
PSY is the first US-listed psychedelic ETF that seeks to track an index of publicly listed companies in North America that operate business models focused on the usage of psychedelics, medical cannabis, and ketamine for medicinal and health treatment purposes. Securities are required to have at least 50% of their revenue from legal activities related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol derivatives, and ketamine. The index’s cap weighting provides limits that mitigate risk of overexposure to any single company. The fund could engage in securities lending of no more than one-third of its total asset value, which brings revenues to the fund at the cost of slight counterparty risk. The index is reconstituted and rebalanced semi-annually every March and September.
PSY Portfolio Data
PSY Index Data
PSY Portfolio Management
PSY Tax Exposures
PSY Fund Structure
PSY Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of PSY. PSY is rated a 1 out of 5.
PSY Economic Development
PSY Performance Statistics
PSY Benchmark Comparison Summary
PSY Benchmark Comparison Market Cap Size
Options Strategies for Outcome Investing
A collar strategy is a protective option strategy constructed by writing a call and buying a put with the same expiration date while being long the underlying security.
A covered call is an income strategy constructed by writing a call option against a holding of the underlying security.